
Meera R Chappidi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2699585/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Lipid-Lowering Drug Use and Cancer Incidence and Mortality in the ARIC Study. JNCI Cancer Spectrum, 2021, 5, pkab080.	2.9	6
2	Urethral Defect in Setting of Recurrent Urethral Foreign Body Insertion. Urology, 2020, 137, e12-e13.	1.0	2
3	Impact of intravesical therapy for non-muscle invasive bladder cancer on the accuracy of urine cytology. World Journal of Urology, 2019, 37, 2051-2058.	2.2	12
4	Prognostic implications of prostatic urethral involvement in non-muscle-invasive bladder cancer. World Journal of Urology, 2019, 37, 2683-2689.	2.2	8
5	Hospitalisation and readmission costs after radical cystectomy in a nationally representative sample: does urinary reconstruction matter?. BJU International, 2018, 122, 1016-1024.	2.5	10
6	Longer average blood storage duration is associated with increased risk of infection and overall morbidity following radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 38.e17-38.e24.	1.6	8
7	Prostate Health Index density improves detection of clinically significant prostate cancer. BJU International, 2017, 120, 793-798.	2.5	69
8	Assessing Cancer Progression and Stable Disease After Neoadjuvant Chemotherapy for Organ-confined Muscle-invasive Bladder Cancer. Urology, 2017, 102, 148-158.	1.0	12
9	Evaluation of genderâ€based disparities in time from initial haematuria presentation to upper tract urothelial carcinoma diagnosis: analysis of a nationwide insurance claims database. BJU International, 2017, 120, 377-386.	2.5	7
10	Erectile Dysfunction Treatment Following Radical Cystoprostatectomy: Analysis of a Nationwide Insurance Claims Database. Journal of Sexual Medicine, 2017, 14, 810-817.	0.6	10
11	Prognostic utility of biopsyâ€derived cell cycle progression score in patients with National Comprehensive Cancer Network Iowâ€risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance. BJU International, 2017, 120, 808-814.	2.5	48
12	Author Reply. Urology, 2017, 102, 158.	1.0	0
13	Analysis of Hospital Readmissions After Prosthetic Urologic Surgery in the United States: Nationally Representative Estimates of Causes, Costs, and Predictive Factors. Journal of Sexual Medicine, 2017, 14, 1059-1065.	0.6	7
14	High dose-rate Intra-Operative Radiation Therapy During High Risk Genitourinary Surgery: Initial Observations and a Proposal for its Study in Bladder Cancer. Bladder Cancer, 2017, 3, 191-199.	0.4	4
15	Quantifying Nonindex Hospital Readmissions and Care Fragmentation after Major Urological Oncology Surgeries in a Nationally Representative Sample. Journal of Urology, 2017, 197, 235-240.	0.4	39
16	Causes, Timing, Hospital Costs and Perioperative Outcomes of Index vs Nonindex Hospital Readmissions after Radical Cystectomy: Implications for Regionalization of Care. Journal of Urology, 2017, 197, 296-301.	0.4	39
17	Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 34.e17-34.e25.	1.6	21
18	Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer. Bladder Cancer, 2017, 3, 293-303.	0.4	60

MEERA R CHAPPIDI

#	Article	IF	CITATIONS
19	Oncological outcomes of intravesical gemcitabine and docetaxel for select patients with high grade recurrent NMIBC Journal of Clinical Oncology, 2017, 35, 4546-4546.	1.6	4
20	Examining gemcitabine and docetaxel for recurrent NMIBC Journal of Clinical Oncology, 2017, 35, 322-322.	1.6	0
21	Accuracy of urethral frozen section during radical cystectomy for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 532.e1-532.e6.	1.6	13
22	Lymph node yield and tumor location in patients with upper tract urothelial carcinoma undergoing nephroureterectomy affects survival: A U.S. population–based analysis (2004–2012). Urologic Oncology: Seminars and Original Investigations, 2016, 34, 531.e15-531.e24.	1.6	27
23	Frailty as a marker of adverse outcomes in patients with bladder cancer undergoing radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 256.e1-256.e6.	1.6	86
24	Contemporary treatment patterns and short-term outcomes in men with very high-risk prostate cancer Journal of Clinical Oncology, 2016, 34, 103-103.	1.6	0
25	Effect of chemotherapy and/or TURBT on pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer Journal of Clinical Oncology, 2016, 34, 395-395.	1.6	0
26	Cost Benefit Analysis Of a Sickle Cell Infusion Center For The Treatment Of Vaso-Occlusive Crises. Blood, 2013, 122, 1697-1697.	1.4	1